Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Immunogenicity, Effectiveness, and Safety of Inactivated Virus (CoronaVac) Vaccine in a Two-Dose Primary Protocol and BNT162b2 Heterologous Booster in Brazil (Immunita-001): A One Year Period Follow Up Phase 4 Study

Frontiers in Immunology(2022)10.3389/fimmu.2022.918896Source: DataRank Database

Immunogenicity, Effectiveness, and Safety of Inactivated Virus (CoronaVac) Vaccine in a Two-Dose Primary Protocol and BNT162b2 Heterologous Booster in Brazil (Immunita-001): A One Year Period Follow Up Phase 4 Study is a research paper published in Frontiers in Immunology (2022). On theSindex it has a DataRank of 0. It has been cited 21 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access21 citations

Free full text

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (2 grants)OA: goldTopics (57)IDs (PubMed)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (23)

Nathalie Bonatti Franco Almeida ORCID,Priscilla Soares Filgueiras ORCID,Camila Amormino Corsini ORCID,Sarah Vieira Contin Gomes ORCID,Daniel Alvim Pena de Miranda ORCID

Live enrichment

PubMed:35757764

National Institutes of Health

Grant: 5U01AI151807-03

Coordinating Research on Emerging Arboviral Threats Encoing the Neotropics (CREATE-NEO)

NIAID NIH HHS

Grant: U01 AI151807

goldLicense: cc-by

publisherhttps://www.frontiersin.org/articles/10.3389/fimmu.2022.918896/pdf

publisherhttps://www.frontiersin.org/articles/10.3389/fimmu.2022.918896/full

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/9218743

repositoryhttps://doaj.org/article/1ea09f5e8d8d44b49fc0a9401610d309

https://doi.org/10.3389/fimmu.2022.918896

Fields of Study

0301 basic medicine03 medical and health sciences0303 health sciencesAntibodies, NeutralizingAntibodies, ViralBNT162 VaccineBrazilCOVID-19COVID-19 VaccinesFemaleFollow-Up StudiesHumansImmunization, SecondaryImmunogenicity, VaccineImmunoglobulin GMalePandemicsSARS-CoV-2SARS-CoV-2 variants

MeSH Terms

Antibodies, NeutralizingAntibodies, ViralBNT162 VaccineBrazilCOVID-19COVID-19 VaccinesFemaleFollow-Up StudiesHumansImmunization, SecondaryImmunogenicity, VaccineImmunoglobulin GMalePandemicsSARS-CoV-2

Keywords

MaleCOVID-19 VaccinesImmunologyImmunization, SecondaryAntibodies, Viralimmune responseImmunogenicity, VaccinevaccineHumansPandemicsBNT162 VaccineSARS-CoV-2COVID-19coronavacRC581-607Antibodies, NeutralizingImmunoglobulin GBNT162b2FemaleImmunologic diseases. AllergyBrazilFollow-Up Studiesheterologous booster

Sustainable Development Goals

SDG 3: 3. Good health